- Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
- Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
- Kronos Bio Reports First-Quarter 2024 Financial Results
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
- Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
- Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
- Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
- Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
- Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
More ▼
Key statistics
On Wednesday, Kronos Bio Inc (KRON:NSQ) closed at 1.00, 36.80% above the 52 week low of 0.731 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.02 |
---|---|
High | 1.05 |
Low | 0.99 |
Bid | 0.9905 |
Offer | 1.03 |
Previous close | 1.02 |
Average volume | 285.12k |
---|---|
Shares outstanding | 60.09m |
Free float | 47.67m |
P/E (TTM) | -- |
Market cap | 61.30m USD |
EPS (TTM) | -2.00 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼